VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$9.15Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $611,000,448.00
EPSttm : -4.28
Verastem, Inc.
$9.15
21.11%$1.59Float Short %
29.42
Margin Of Safety %
Put/Call OI Ratio
0.5
EPS Next Q Diff
0.84
EPS Last/This Y
0.94
EPS This/Next Y
1.05
Price
9.15
Target Price
16
Analyst Recom
1
Performance Q
17.46
Relative Volume
1.86
Beta
0.47
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-20 | VSTM | 8.02 | 0.19 | 0.68 | 12026 |
| 2025-10-21 | VSTM | 8 | 0.27 | 0.34 | 15227 |
| 2025-10-22 | VSTM | 7.84 | 0.27 | 4.89 | 15485 |
| 2025-10-23 | VSTM | 7.82 | 0.29 | 0.04 | 15752 |
| 2025-10-24 | VSTM | 7.96 | 0.29 | 0.21 | 15766 |
| 2025-10-27 | VSTM | 8.7 | 0.29 | 0.28 | 15905 |
| 2025-10-28 | VSTM | 8.85 | 0.29 | 0.30 | 16009 |
| 2025-10-29 | VSTM | 8.81 | 0.29 | 0.01 | 16017 |
| 2025-10-30 | VSTM | 9.21 | 0.29 | 0.00 | 16116 |
| 2025-10-31 | VSTM | 9.45 | 0.26 | 0.03 | 17214 |
| 2025-11-03 | VSTM | 9.9 | 0.26 | 0.39 | 17272 |
| 2025-11-04 | VSTM | 7.91 | 0.26 | 1.40 | 17305 |
| 2025-11-05 | VSTM | 8.16 | 0.42 | 4.54 | 22378 |
| 2025-11-06 | VSTM | 7.91 | 0.46 | 0.00 | 22850 |
| 2025-11-07 | VSTM | 8.06 | 0.46 | 1.69 | 22844 |
| 2025-11-10 | VSTM | 8.27 | 0.46 | 0.15 | 22816 |
| 2025-11-11 | VSTM | 8.46 | 0.46 | 0.19 | 22835 |
| 2025-11-12 | VSTM | 8.52 | 0.46 | 0.05 | 22840 |
| 2025-11-13 | VSTM | 8.12 | 0.46 | 2.73 | 23004 |
| 2025-11-14 | VSTM | 7.55 | 0.47 | 1.49 | 23148 |
| 2025-11-17 | VSTM | 9.15 | 0.50 | 0.29 | 23705 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-20 | VSTM | 8.02 | 31.1 | - | -2.44 |
| 2025-10-21 | VSTM | 8.00 | 31.1 | - | -2.44 |
| 2025-10-22 | VSTM | 7.86 | 31.1 | - | -2.44 |
| 2025-10-23 | VSTM | 7.81 | 31.1 | - | -2.44 |
| 2025-10-24 | VSTM | 7.95 | 31.1 | - | -2.44 |
| 2025-10-27 | VSTM | 8.69 | 31.1 | - | -2.44 |
| 2025-10-28 | VSTM | 8.85 | 31.1 | - | -2.44 |
| 2025-10-29 | VSTM | 8.81 | 31.1 | - | -2.44 |
| 2025-10-30 | VSTM | 9.23 | 31.1 | - | -2.44 |
| 2025-10-31 | VSTM | 9.45 | 31.1 | - | -2.44 |
| 2025-11-03 | VSTM | 9.90 | 31.1 | - | -2.44 |
| 2025-11-04 | VSTM | 7.91 | 31.1 | - | -2.44 |
| 2025-11-05 | VSTM | 8.15 | 31.1 | - | -2.44 |
| 2025-11-06 | VSTM | 7.91 | 31.1 | - | -2.44 |
| 2025-11-07 | VSTM | 8.07 | 1.7 | - | -2.45 |
| 2025-11-10 | VSTM | 8.25 | 1.7 | - | -2.45 |
| 2025-11-11 | VSTM | 8.45 | 1.7 | - | -2.45 |
| 2025-11-12 | VSTM | 8.53 | 1.7 | - | -2.45 |
| 2025-11-13 | VSTM | 8.11 | 1.7 | - | -2.45 |
| 2025-11-14 | VSTM | 7.55 | 1.7 | - | -2.45 |
| 2025-11-17 | VSTM | 9.15 | 30.0 | - | -2.73 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-20 | VSTM | -2.30 | 1.09 | 30.60 |
| 2025-10-21 | VSTM | -2.30 | 1.09 | 30.60 |
| 2025-10-22 | VSTM | -2.30 | 1.09 | 30.60 |
| 2025-10-23 | VSTM | -2.30 | 1.09 | 30.60 |
| 2025-10-24 | VSTM | -2.30 | 1.09 | 30.60 |
| 2025-10-27 | VSTM | -2.30 | 1.00 | 31.69 |
| 2025-10-28 | VSTM | -2.30 | 1.00 | 31.69 |
| 2025-10-29 | VSTM | -1.63 | 1.00 | 32.76 |
| 2025-10-30 | VSTM | -1.63 | 1.00 | 32.76 |
| 2025-10-31 | VSTM | -1.63 | 1.00 | 32.76 |
| 2025-11-03 | VSTM | -1.63 | -1.13 | 32.76 |
| 2025-11-04 | VSTM | -1.63 | -1.13 | 32.76 |
| 2025-11-05 | VSTM | -1.63 | -1.13 | 32.76 |
| 2025-11-06 | VSTM | -1.55 | -1.13 | 32.76 |
| 2025-11-07 | VSTM | -1.55 | -1.13 | 30.19 |
| 2025-11-10 | VSTM | -1.54 | 7.24 | 30.19 |
| 2025-11-11 | VSTM | -1.54 | 7.24 | 30.19 |
| 2025-11-12 | VSTM | -1.54 | 7.24 | 29.42 |
| 2025-11-13 | VSTM | -1.54 | 7.24 | 29.42 |
| 2025-11-14 | VSTM | -1.54 | 7.24 | 29.42 |
| 2025-11-17 | VSTM | -1.54 | 19.40 | 29.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.35
Avg. EPS Est. Current Quarter
-0.42
Avg. EPS Est. Next Quarter
-0.51
Insider Transactions
-1.54
Institutional Transactions
19.4
Beta
0.47
Average Sales Estimate Current Quarter
15
Average Sales Estimate Next Quarter
18
Fair Value
Quality Score
5
Growth Score
46
Sentiment Score
42
Actual DrawDown %
84.6
Max Drawdown 5-Year %
-96.2
Target Price
16
P/E
Forward P/E
PEG
P/S
45.66
P/B
P/Free Cash Flow
EPS
-4.26
Average EPS Est. Cur. Y
-2.73
EPS Next Y. (Est.)
-1.67
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1802.12
Relative Volume
1.86
Return on Equity vs Sector %
Return on Equity vs Industry %
EPS 1 7Days Diff
-0.3
EPS 1 30Days Diff
-0.29
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 78
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading